

Julie Chao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1098000/publications.pdf>

Version: 2024-02-01

185
papers

8,922
citations

24978

57
h-index

62479

80
g-index

185
all docs

185
docs citations

185
times ranked

5706
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase Akt Pathway Mediates Nitric Oxide-Induced Endothelial Cell Migration and Angiogenesis. <i>Molecular and Cellular Biology</i> , 2003, 23, 5726-5737.	1.1	248
2	Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in Mouse Model of Hindlimb Ischemia. <i>Circulation</i> , 2001, 103, 125-132.	1.6	186
3	Kallistatin is a new inhibitor of angiogenesis and tumor growth. <i>Blood</i> , 2002, 100, 3245-3252.	0.6	164
4	Structure and Chromosomal Localization of the Gene (BDKRB2) Encoding Human Bradykinin B2 Receptor. <i>Genomics</i> , 1994, 23, 362-369.	1.3	151
5	The Radioimmunoassay of Human Urinary Kallikrein and Comparisons with Kallikrein Activity Measurements*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 51, 840-848.	1.8	130
6	Adrenomedullin Protects Against Myocardial Apoptosis After Ischemia/Reperfusion Through Activation of Akt-GSK Signaling. <i>Hypertension</i> , 2004, 43, 109-116.	1.3	121
7	Transcription Factor Nuclear Factor κ B Regulates the Inducible Expression of the Human B1 Receptor Gene in Inflammation. <i>Journal of Biological Chemistry</i> , 1998, 273, 2784-2791.	1.6	120
8	Adrenomedullin Gene Delivery Attenuates Hypertension, Cardiac Remodeling, and Renal Injury in Deoxycorticosterone Acetate-Salt Hypertensive Rats. <i>Hypertension</i> , 2000, 36, 995-1001.	1.3	117
9	Tissue Kallikrein in Rat Brain and Pituitary: Regional Distribution and Estrogen Induction in the Anterior Pituitary*. <i>Endocrinology</i> , 1987, 120, 475-482.	1.4	114
10	Kallikrein Gene Delivery Attenuates Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion. <i>Hypertension</i> , 2000, 35, 25-31.	1.3	113
11	Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. <i>FASEB Journal</i> , 2000, 14, 1858-1860.	0.2	112
12	Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis. <i>Human Gene Therapy</i> , 2006, 17, 206-219.	1.4	110
13	Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. <i>Translational Research</i> , 1996, 127, 612-620.	2.4	107
14	Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis. <i>Hypertension</i> , 2004, 43, 452-459.	1.3	105
15	Kallikrein/Kinin Protects against Myocardial Apoptosis after Ischemia/Reperfusion via Akt-Glycogen Synthase Kinase-3 and Akt-Bad \hat{A} -14-3-3 Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2005, 280, 8022-8030.	1.6	105
16	Genomic DNA Sequence, Expression, and Chromosomal Localization of the Human B1 Bradykinin Receptor Gene BDKRB1. <i>Genomics</i> , 1996, 31, 51-57.	1.3	103
17	Human Kallikrein Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy, and Renal Injury in Dahl Salt-Sensitive Rats. <i>Human Gene Therapy</i> , 1998, 9, 21-31.	1.4	99
18	Kallikrein \hat{A} -kinin in stroke, cardiovascular and renal disease. <i>Experimental Physiology</i> , 2005, 90, 291-298.	0.9	95

#	ARTICLE	IF	CITATIONS
19	Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 624-633.	0.4	95
20	Kallikrein-Modified Mesenchymal Stem Cell Implantation Provides Enhanced Protection Against Acute Ischemic Kidney Injury by Inhibiting Apoptosis and Inflammation. <i>Human Gene Therapy</i> , 2008, 19, 807-819.	1.4	95
21	Prolonged Reduction of High Blood Pressure With Human Nitric Oxide Synthase Gene Delivery. <i>Hypertension</i> , 1997, 30, 307-313.	1.3	92
22	Postischemic Brain Injury Is Exacerbated in Mice Lacking the Kinin B2 Receptor. <i>Hypertension</i> , 2006, 47, 752-761.	1.3	89
23	Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. <i>Biological Chemistry</i> , 2010, 391, 345-55.	1.2	88
24	Kallikrein Gene Delivery Attenuates Hypertension and Cardiac Hypertrophy and Enhances Renal Function in Goldblatt Hypertensive Rats. <i>Hypertension</i> , 1998, 31, 1104-1110.	1.3	86
25	Human Endothelial Nitric Oxide Synthase Gene Delivery Promotes Angiogenesis in a Rat Model of Hindlimb Ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1279-1285.	1.1	86
26	Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. <i>Arthritis and Rheumatism</i> , 2005, 52, 1319-1324.	6.7	86
27	Kallikrein Gene Delivery Improves Cardiac Reserve and Attenuates Remodeling After Myocardial Infarction. <i>Hypertension</i> , 2002, 40, 653-659.	1.3	84
28	Salutary Effect of Kallistatin in Salt-Induced Renal Injury, Inflammation, and Fibrosis via Antioxidative Stress. <i>Hypertension</i> , 2008, 51, 1358-1365.	1.3	82
29	Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. <i>Life Sciences</i> , 2005, 76, 2457-2471.	2.0	80
30	Prevention of Diabetes-Induced Microangiopathy by Human Tissue Kallikrein Gene Transfer. <i>Circulation</i> , 2002, 106, 993-999.	1.6	78
31	Hypotension in Transgenic Mice Overexpressing Human Bradykinin B2Receptor. <i>Hypertension</i> , 1997, 29, 488-493.	1.3	76
32	Adenovirus-Mediated Human Tissue Kallikrein Gene Delivery Induces Angiogenesis in Normoperfused Skeletal Muscle. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2379-2385.	1.1	76
33	Isozymes of rat urinary kallikrein. <i>Biochemical Pharmacology</i> , 1979, 28, 2071-2079.	2.0	75
34	Rescue of Impaired Angiogenesis in Spontaneously Hypertensive Rats by Intramuscular Human Tissue Kallikrein Gene Transfer. <i>Hypertension</i> , 2001, 38, 136-141.	1.3	75
35	Novel Role of Kallistatin in Protection Against Myocardial Ischemiaâ€“Reperfusion Injury by Preventing Apoptosis and Inflammation. <i>Human Gene Therapy</i> , 2006, 17, 1201-1213.	1.4	74
36	Kruppel-like Factor 4 Is a Novel Mediator of Kallistatin in Inhibiting Endothelial Inflammation via Increased Endothelial Nitric-oxide Synthase Expression. <i>Journal of Biological Chemistry</i> , 2009, 284, 35471-35478.	1.6	74

#	ARTICLE	IF	CITATIONS
37	Kallistatin inhibits TGF- β 2-induced endothelial \rightarrow mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. <i>Experimental Cell Research</i> , 2015, 337, 103-110.	1.2	74
38	Kallistatin reduces vascular senescence and aging by regulating microRNA-34a \rightarrow SIRT1 pathway. <i>Aging Cell</i> , 2017, 16, 837-846.	3.0	74
39	Localization and Expression of Tissue Kallikrein and Kallistatin in Human Blood Vessels. <i>Journal of Histochemistry and Cytochemistry</i> , 1999, 47, 221-228.	1.3	73
40	Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. <i>Kidney International</i> , 2000, 58, 730-739.	2.6	72
41	Human Adrenomedullin Gene Delivery Protects against Cardiac Hypertrophy, Fibrosis, and Renal Damage in Hypertensive Dahl Salt-Sensitive Rats. <i>Human Gene Therapy</i> , 2000, 11, 1817-1827.	1.4	70
42	Kallikrein Gene Delivery Improves Serum Glucose and Lipid Profiles and Cardiac Function in Streptozotocin-Induced Diabetic Rats. <i>Diabetes</i> , 2005, 54, 1573-1580.	0.3	70
43	Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H1419-H1427.	1.5	70
44	Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. <i>Scientific Reports</i> , 2015, 5, 12463.	1.6	70
45	The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. <i>Biological Chemistry</i> , 2006, 387, 665-75.	1.2	66
46	Kallikrein Multigene Families and the Regulation of Their Expression. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, S7-S16.	0.8	66
47	Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats. <i>Hypertension</i> , 1995, 26, 847-853.	1.3	66
48	Atrial Natriuretic Peptide Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy, and Renal Injury in Salt-Sensitive Rats. <i>Human Gene Therapy</i> , 1998, 9, 1429-1438.	1.4	65
49	Proteomic Analysis Reveals Alterations in the Renal Kallikrein Pathway during Hypoxia-Induced Hypertension. <i>Journal of Biological Chemistry</i> , 2002, 277, 34708-34716.	1.6	65
50	Overexpression of Kinin B1 Receptors Induces Hypertensive Response to Des-Arg9-bradykinin and Susceptibility to Inflammation. <i>Journal of Biological Chemistry</i> , 2003, 278, 219-225.	1.6	65
51	Kallistatin Inhibits Vascular Inflammation by Antagonizing Tumor Necrosis Factor- α -Induced Nuclear Factor κ B Activation. <i>Hypertension</i> , 2010, 56, 260-267.	1.3	65
52	Muscle Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive Rats. <i>Hypertension</i> , 1995, 25, 715-719.	1.3	65
53	Regulation of bradykinin B2 -receptor expression by oestrogen. <i>British Journal of Pharmacology</i> , 1997, 121, 1763-1769.	2.7	64
54	Kallikrein activation of a high molecular weight atrial peptide. <i>Biochemical and Biophysical Research Communications</i> , 1984, 120, 461-466.	1.0	62

#	ARTICLE	IF	CITATIONS
55	Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation. <i>Hypertension</i> , 2008, 52, 715-720.	1.3	59
56	A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: Activation of proteinase-activated receptor 1 and epidermal growth factor receptor. <i>Experimental Cell Research</i> , 2010, 316, 376-389.	1.2	58
57	Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. <i>Biological Chemistry</i> , 2010, 391, 411-23.	1.2	58
58	Molecular cloning and expression of rat bradykinin B1 receptor. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1442, 177-185.	2.4	57
59	Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. <i>Kidney International</i> , 2004, 66, 722-732.	2.6	57
60	Kinin Infusion Prevents Renal Inflammation, Apoptosis, and Fibrosis via Inhibition of Oxidative Stress and Mitogen-Activated Protein Kinase Activity. <i>Hypertension</i> , 2007, 49, 490-497.	1.3	57
61	Protective Role of Kallistatin in Vascular and Organ Injury. <i>Hypertension</i> , 2016, 68, 533-541.	1.3	57
62	Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, F964-F971.	1.3	56
63	Gene Therapy With Human Tissue Kallikrein Reduces Hypertension and Hyperinsulinemia in Fructose-Induced Hypertensive Rats. <i>Hypertension</i> , 2003, 42, 1026-1033.	1.3	55
64	Reversal of Renal Fibrosis, Inflammation, and Glomerular Hypertrophy by Kallikrein Gene Delivery. <i>Human Gene Therapy</i> , 2006, 17, 545-555.	1.4	55
65	Kallikrein Gene Delivery Inhibits Vascular Smooth Muscle Cell Growth and Neointima Formation in the Rat Artery After Balloon Angioplasty. <i>Hypertension</i> , 1999, 34, 164-170.	1.3	54
66	A Synthetic Tissue Kallikrein Inhibitor Suppresses Cancer Cell Invasiveness. <i>American Journal of Pathology</i> , 2001, 159, 1797-1805.	1.9	54
67	Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. <i>Laboratory Investigation</i> , 2008, 88, 1157-1166.	1.7	54
68	Adrenomedullin Gene Delivery Reduces Blood Pressure in Spontaneously Hypertensive Rats. <i>Hypertension Research</i> , 1997, 20, 269-277.	1.5	54
69	Differential Effects of Testosterone, Thyroxine, and Cortisol on Rat Submandibular Gland Versus Renal Kallikrein*. <i>Endocrinology</i> , 1983, 113, 2221-2225.	1.4	53
70	Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. <i>Journal of Hypertension</i> , 1989, 7, 865-871.	0.3	53
71	Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. <i>Kidney International</i> , 1995, 48, 690-697.	2.6	53
72	Intermedin is a new angiogenic growth factor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H1040-H1047.	1.5	52

#	ARTICLE	IF	CITATIONS
73	Identification of a Major Heparin-binding Site in Kallistatin. <i>Journal of Biological Chemistry</i> , 2001, 276, 1276-1284.	1.6	51
74	Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3 β pathway. <i>Cardiovascular Research</i> , 2008, 80, 354-364.	1.8	51
75	Structural elements of kallistatin required for inhibition of angiogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2003, 284, C1604-C1613.	2.1	50
76	Tissue Kallikrein Reverses Insulin Resistance and Attenuates Nephropathy in Diabetic Rats by Activation of Phosphatidylinositol 3-Kinase/Protein Kinase B and Adenosine 5'-Monophosphate-Activated Protein Kinase Signaling Pathways. <i>Endocrinology</i> , 2007, 148, 2016-2026.	1.4	50
77	Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. <i>Peptides</i> , 2001, 22, 1731-1737.	1.2	49
78	Novel Roles of Kallistatin, a Specific Tissue Kallikrein Inhibitor, in Vascular Remodeling. <i>Biological Chemistry</i> , 2001, 382, 15-21.	1.2	49
79	Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3 β activation. <i>Cardiovascular Research</i> , 2007, 73, 130-142.	1.8	49
80	Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. <i>Experimental Cell Research</i> , 2016, 340, 305-314.	1.2	49
81	Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. <i>Biochemistry</i> , 1992, 31, 4969-4974.	1.2	47
82	Association of the tissue kallikrein gene promoter with ESRD and hypertension. <i>Kidney International</i> , 2002, 61, 1030-1039.	2.6	47
83	Role of Tissue Kallikrein in Prevention and Recovery of Gentamicin-Induced Renal Injury. <i>Toxicological Sciences</i> , 2008, 102, 433-443.	1.4	47
84	Adenovirus-Mediated Delivery of Human Kallistatin Gene Reduces Blood Pressure of Spontaneously Hypertensive Rats. <i>Human Gene Therapy</i> , 1997, 8, 341-347.	1.4	46
85	Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. <i>Kidney International</i> , 1998, 54, 1250-1260.	2.6	46
86	Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. <i>Regulatory Peptides</i> , 2007, 140, 12-20.	1.9	46
87	Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-8.	1.9	45
88	Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H1479-H1488.	1.5	44
89	Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. <i>Life Sciences</i> , 2008, 82, 156-165.	2.0	44
90	Adenovirus-Mediated Kallistatin Gene Transfer Ameliorates Disease Progression in a Rat Model of Osteoarthritis Induced by Anterior Cruciate Ligament Transection. <i>Human Gene Therapy</i> , 2009, 20, 147-158.	1.4	44

#	ARTICLE	IF	CITATIONS
91	Intramuscular Delivery of Rat Kallikrein-binding Protein Gene Reverses Hypotension in Transgenic Mice Expressing Human Tissue Kallikrein. <i>Journal of Biological Chemistry</i> , 1995, 270, 451-455.	1.6	43
92	Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. <i>Current Eye Research</i> , 1996, 15, 1117-1123.	0.7	43
93	Atrial Natriuretic Peptide Gene Delivery Reduces Stroke-Induced Mortality Rate in Dahl Salt-Sensitive Rats. <i>Hypertension</i> , 1999, 33, 219-224.	1.3	43
94	Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. <i>Immunology</i> , 2014, 142, 216-226.	2.0	43
95	A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. <i>Journal of Hypertension</i> , 1988, 6, 551-558.	0.3	42
96	Systemic and Portal Vein Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive Rats. <i>Human Gene Therapy</i> , 1996, 7, 901-911.	1.4	42
97	Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. <i>Kidney International</i> , 1998, 53, 1305-1313.	2.6	41
98	Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. <i>Peptides</i> , 2007, 28, 1383-1389.	1.2	41
99	Roles of the P1, P2, and P3 Residues in Determining Inhibitory Specificity of Kallistatin toward Human Tissue Kallikrein. <i>Journal of Biological Chemistry</i> , 2000, 275, 38457-38466.	1.6	40
100	Gene Therapy in Hypertension: Adenovirus-Mediated Kallikrein Gene Delivery in Hypertensive Rats. <i>Human Gene Therapy</i> , 1997, 8, 1753-1761.	1.4	39
101	Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H1048-H1054.	1.5	39
102	Kallistatin Modulates Immune Cells and Confers Anti-Inflammatory Response To Protect Mice from Group A Streptococcal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5366-5372.	1.4	39
103	Adenovirus-Mediated Kallikrein Gene Delivery Reduces Aortic Thickening and Stroke-Induced Death Rate in Dahl Salt-Sensitive Rats. <i>Stroke</i> , 1999, 30, 1925-1932.	1.0	38
104	Kallistatin antagonizes Wnt/ β 2-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. <i>Molecular and Cellular Biochemistry</i> , 2013, 379, 295-301.	1.4	38
105	Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F1230-F1238.	1.3	37
106	Beneficial effects of Kallikrein-binding protein in transgenic mice during endotoxic shock. <i>Life Sciences</i> , 1997, 60, 1431-1435.	2.0	35
107	Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. <i>Immunopharmacology</i> , 1999, 44, 57-65.	2.0	35
108	The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 1999, 126, 1769-1776.	2.7	35

#	ARTICLE	IF	CITATIONS
109	Plasma kallistatin levels in patients with severe community-acquired pneumonia. <i>Critical Care</i> , 2013, 17, R27.	2.5	35
110	Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1986, 867, 16-23.	2.4	34
111	Kallikrein-Kinin System and Blood Pressure Sensitivity to Salt. <i>Hypertension</i> , 1997, 29, 471-477.	1.3	34
112	Experimental therapy with tissue kallikrein against cerebral ischemia. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1323.	3.0	33
113	Activation of serpins and their cognate proteases in muscle after crush injury. <i>Journal of Cellular Physiology</i> , 1994, 159, 11-18.	2.0	32
114	Molecular Cloning, Sequence Analysis, and Chromosomal Localization of the Human Protease Inhibitor 4 (Kallistatin) Gene (PI4). <i>Genomics</i> , 1994, 23, 370-378.	1.3	32
115	Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. <i>Critical Care</i> , 2015, 19, 200.	2.5	32
116	Kallistatin Stimulates Vascular Smooth Muscle Cell Proliferation and Migration In Vitro and Neointima Formation in Balloon-Injured Rat Artery. <i>Circulation Research</i> , 2000, 86, 418-424.	2.0	31
117	Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. <i>BBA - Proteins and Proteomics</i> , 2000, 1479, 237-246.	2.1	30
118	Enhanced renal function in bradykinin B ₂ receptor transgenic mice. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, F484-F491.	1.3	30
119	Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. <i>BMC Cancer</i> , 2010, 10, 245.	1.1	30
120	Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. <i>Biological Chemistry</i> , 2010, 391, 803-12.	1.2	30
121	DNA polymorphisms in the 5' flanking region of the human tissue kallikrein gene. <i>Human Genetics</i> , 1997, 99, 727-734.	1.8	29
122	Functional Analysis of Human Tissue Kallikrein in Transgenic Mouse Models. <i>Hypertension</i> , 1996, 27, 491-494.	1.3	29
123	Tissue Kallikrein-binding Protein Reduces Blood Pressure in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 1996, 271, 27590-27594.	1.6	28
124	Adenovirus-Mediated Human Tissue Kallikrein Gene Delivery Inhibits Neointima Formation Induced by Interruption of Blood Flow in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1459-1466.	1.1	28
125	Tissue Kallikrein and Kinin Infusion Rescues Failing Myocardium After Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2007, 13, 588-596.	0.7	28
126	Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1987, 910, 233-239.	2.4	27

#	ARTICLE	IF	CITATIONS
127	High Level of Circulating Human Tissue Kallikrein Induces Hypotension in a Transgenic Mouse Model. <i>Clinical and Experimental Hypertension</i> , 1996, 18, 975-993.	0.5	27
128	Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F622-F631.	1.3	27
129	Novel Role of Kallistatin in Vascular Repair by Promoting Mobility, Viability, and Function of Endothelial Progenitor Cells. <i>Journal of the American Heart Association</i> , 2014, 3, e001194.	1.6	27
130	Human urinary kallikrein Complete amino acid sequence and sites of glycosylation. <i>International Journal of Peptide and Protein Research</i> , 1989, 33, 237-249.	0.1	26
131	Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 642-646.	1.5	26
132	Kallistatin attenuates endothelial senescence by modulating Letâ€“gâ€“mediated miRâ€“34aâ€“SIRTâ€“eNOSâ€“ pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4387-4398.	1.6	25
133	A Positively Charged Loop on the Surface of Kallistatin Functions to Enhance Tissue Kallikrein Inhibition by Acting as a Secondary Binding Site for Kallikrein. <i>Journal of Biological Chemistry</i> , 2000, 275, 40371-40377.	1.6	24
134	Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?. <i>Physiological Genomics</i> , 2001, 7, 79-94.	1.0	24
135	DNA polymorphisms in the 5â€“flanking region of the human tissue kallikrein gene. <i>Human Genetics</i> , 1997, 99, 727.	1.8	24
136	Specificity of human tissue kallikrein towards substrates containing Pheâ€“Phe pair of amino acids. <i>Biochemical Journal</i> , 1999, 339, 473-479.	1.7	23
137	Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. <i>Biological Chemistry</i> , 2008, 389, 725-730.	1.2	23
138	Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F1033-F1040.	1.3	22
139	Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. <i>Biological Chemistry</i> , 2017, 398, 1309-1317.	1.2	21
140	Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2receptor in SHR. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, F476-F484.	1.3	20
141	Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D. <i>The Protein Journal</i> , 2000, 19, 411-418.	1.1	20
142	Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-7.	1.9	19
143	Antisense Inhibition of the Brain Kallikrein-Kinin System. <i>Hypertension</i> , 1996, 28, 980-987.	1.3	19
144	Glandular Kallikrein Gene Expression is Selectively Down-Regulated by Glucocorticoids in Pancreatic AR42 J Cells*. <i>Endocrinology</i> , 1991, 128, 2216-2222.	1.4	18

#	ARTICLE	IF	CITATIONS
145	Central Delivery of Human Tissue Kallikrein Gene Reduces Blood Pressure in Hypertensive Rats. <i>Biochemical and Biophysical Research Communications</i> , 1998, 244, 449-454.	1.0	18
146	Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. <i>Immunopharmacology</i> , 1999, 44, 137-143.	2.0	18
147	Kallistatin Ameliorates Influenza Virus Pathogenesis by Inhibition of Kallikrein-Related Peptidase 1-Mediated Cleavage of Viral Hemagglutinin. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5619-5630.	1.4	18
148	Kallistatin suppresses cancer development by multi-factorial actions. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 71-78.	2.0	18
149	Upregulation of kallistatin expression in rheumatoid joints. <i>Journal of Rheumatology</i> , 2007, 34, 2171-6.	1.0	18
150	Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1991, 1129, 127-130.	2.4	17
151	Tissue kallikrein inhibitors in mammals. <i>Immunopharmacology</i> , 1996, 32, 67-72.	2.0	17
152	Human Tissue Kallikrein Attenuates Hypertension and Secretes into Circulation and Urine After Intramuscular Gene Delivery in Hypertensive Rats. <i>Clinical and Experimental Hypertension</i> , 1999, 21, 1145-1160.	0.5	17
153	Plasma kallistatin in critically ill patients with severe sepsis and septic shock. <i>PLoS ONE</i> , 2017, 12, e0178387.	1.1	17
154	Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. <i>Immunopharmacology</i> , 1997, 36, 221-227.	2.0	16
155	Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. <i>Journal of the American Heart Association</i> , 2018, 7, e009562.	1.6	16
156	Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. <i>Biochemistry</i> , 1992, 31, 10922-10928.	1.2	15
157	A method for determination of human urinary inactive kallikrein (prekallikrein).. <i>Tohoku Journal of Experimental Medicine</i> , 1982, 137, 269-274.	0.5	14
158	Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-8.	1.9	14
159	Human tissue kallikrein in the treatment of acute ischemic stroke. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641882191.	1.5	14
160	High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. <i>Immunopharmacology</i> , 1996, 32, 105-107.	2.0	13
161	Adenovirus-Mediated eNOS Expression Augments Liver Injury after Ischemia/Reperfusion in Mice. <i>PLoS ONE</i> , 2014, 9, e93304.	1.1	12
162	Protective role of kallistatin in renal fibrosis via modulation of Wnt/ β 2-catenin signaling. <i>Clinical Science</i> , 2021, 135, 429-446.	1.8	12

#	ARTICLE	IF	CITATIONS
163	Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse. <i>British Journal of Pharmacology</i> , 2000, 130, 1076-1082.	2.7	11
164	The Purification of Human Urinary Kallikrein with Ion-Exchange Radial Flow Membrane Chromatography. , 1996, 10, 139-143.		10
165	Differential Developmental Expression of the Rat Kininogen Genes. <i>Pediatric Research</i> , 1992, 32, 649-653.	1.1	9
166	Kallistatin in Blood Pressure Regulation. <i>Trends in Cardiovascular Medicine</i> , 1997, 7, 307-311.	2.3	8
167	Human Kallistatin, a New Tissue Kallikrein-Binding Protein: Purification and Characterization. <i>Advances in Experimental Medicine and Biology</i> , 1989, 247B, 1-8.	0.8	8
168	A simple procedure for high efficiency counting of labeled protein bands in polyacrylamide slab gels. <i>Electrophoresis</i> , 1981, 2, 60-63.	1.3	7
169	Gene Therapy for Hypertension. <i>BioDrugs</i> , 1999, 11, 43-53.	2.2	7
170	Tissue kallikrein is related to the severity of coronary artery disease. <i>Clinica Chimica Acta</i> , 2013, 423, 90-98.	0.5	7
171	Kallikrein-kinin in stem cell therapy. <i>World Journal of Stem Cells</i> , 2014, 6, 448.	1.3	6
172	Tissue Kallikrein-Kinin Therapy in Hypertension and Organ Damage. , 2014, 69, 37-57.		5
173	Circulating Autoantibodies to Mammalian Tissue Kallikreins. <i>Experimental Biology and Medicine</i> , 1988, 187, 320-326.	1.1	4
174	Kallikrein-binding protein is induced by growth hormone in the dwarf rat. <i>FASEB Journal</i> , 1999, 13, 1839-1844.	0.2	4
175	Urinary Levels of Kallikrein and Kallistatin in Pregnancy-Induced Hypertension. <i>Hypertension in Pregnancy</i> , 1995, 14, 201-212.	0.5	3
176	Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, F783-F789.	1.3	3
177	Tissue kallikreins in evolutionarily diverse vertebrates. <i>Immunopharmacology</i> , 1996, 32, 94-95.	2.0	2
178	[14] Adenovirus-mediated gene transfer for cardiovascular and renal diseases. <i>Methods in Enzymology</i> , 2002, 346, 247-263.	0.4	1
179	Human Kallikrein 1, Tissue Kallikrein. , 2013, , 2757-2761.		0
180	Mouse Kallikrein 9, Epidermal Growth Factor-binding Protein. , 2013, , 2830-2831.		0

#	ARTICLE	IF	CITATIONS
181	Kallistatin in Sepsis: Protective Actions and Potential Therapeutic Applications. , 2017, , .		0
182	Rat Tissue Kallikrein. , 2013, , 2835-2837.		0
183	Mouse Î³-nerve Growth Factor. , 2013, , 2831-2833.		0
184	Rat Kallikrein 10, Salivary Gland Proteinase K. , 2013, , 2840-2841.		0
185	Mouse Proteinase F. , 2013, , 2833-2834.		0